Cholangitis vs. Cholecystitis: Key Differences Explained

If you're experiencing severe pain in the upper right side of your abdomen, you might hear the terms cholangitis and cholecystitis. While they sound similar and affect the same part of the body—the biliary system—they are distinct conditions with different locations, severities, and treatments.

Understanding the difference is crucial because while both require medical attention, one is often a more immediate medical emergency. This article breaks down everything you need to know about cholangitis vs. cholecystitis, synthesizing information from leading medical sources to provide a clear and comprehensive guide.

At a Glance: Cholangitis vs. Cholecystitis

Both conditions are inflammatory and typically caused by gallstones, but they affect different parts of your biliary system.

Feature	Cholecystitis	Cholangitis
Location	Inflammation of the gallbladder.	Inflammation and infection of the bile ducts.
Primary Cause	A gallstone blocking the cystic duct (the tube leading out of the gallbladder).	A gallstone or other blockage in the common bile duct, leading to bacterial infection.
Key Symptoms	Persistent RUQ pain, fever, nausea, positive Murphy's sign (pain on inspiration when the area is pressed).	Charcot's Triad: Fever, Jaundice, and RUQ pain. May progress to Reynolds' Pentad (adding confusion and low blood pressure).
Severity	Can be serious, but usually less immediately life-threatening.	Often a medical emergency due to the high risk of sepsis (a widespread blood infection).
Main Treatment	Surgical removal of the gallbladder (cholecystectomy).	Urgent biliary drainage (often via ERCP) and strong antibiotics.

---

What is Cholecystitis (Gallbladder Inflammation)?

Cholecystitis is the inflammation of the gallbladder, a small, pear-shaped organ located beneath the liver. Its main job is to store and concentrate bile, a fluid that helps digest fats. According to the Cleveland Clinic, the suffix "-itis" means inflammation, so cholecystitis literally means "inflammation of the bile bladder."

When the gallbladder becomes inflamed, it can no longer contract and release bile effectively. This dysfunction disrupts normal digestion and triggers a localized inflammatory cascade. If left untreated, the trapped bile and mounting pressure within the gallbladder wall can compromise blood supply, leading to tissue necrosis.

!Anatomy of the Gallbladder and Bile Ducts Image: The biliary system, showing the gallbladder and the network of bile ducts. In cholecystitis, the gallbladder itself is inflamed. In cholangitis, the ducts (such as the common bile duct) are inflamed. Source: Wikimedia Commons

Causes and Risk Factors of Cholecystitis

The vast majority of cholecystitis cases (over 90%) are caused by gallstones (cholelithiasis) blocking the cystic duct. When bile can't escape the gallbladder, it builds up, causing pressure, irritation, and inflammation. This form is known as calculous cholecystitis. Over time, the concentrated bile salts and stagnant fluid irritate the mucosal lining, triggering the release of inflammatory mediators like phospholipase A and prostaglandins. This leads to edema, increased vascular permeability, and the classic clinical presentation of acute cholecystitis.

A smaller percentage of cases occur without gallstones, a condition termed acalculous cholecystitis. This variant typically develops in critically ill patients, such as those recovering from major trauma, severe burns, prolonged total parenteral nutrition (TPN), or those in intensive care units experiencing sepsis. In acalculous cholecystitis, bile stasis results from hypoperfusion (reduced blood flow to the gallbladder) rather than physical obstruction, making it a highly dangerous condition that requires rapid recognition and intervention.

Common risk factors for developing the gallstones that lead to cholecystitis are often summarized by the "5 Fs":

• Fat: Obesity (BMI > 30) is a major risk factor. Excess body weight increases cholesterol secretion into bile, promoting stone formation.
• Female: Women are more susceptible than men due to hormonal influences on bile composition.
• Fertile: Increased estrogen from pregnancy can raise cholesterol in bile and decrease gallbladder motility, leading to stasis.
• Forty: The risk increases with age, particularly after 40, as gallbladder function naturally declines and bile becomes more concentrated.
• Fair: Individuals of European or Hispanic descent have a higher prevalence of gallstone disease due to genetic predispositions in cholesterol metabolism.

A family history of gallstones is often considered a sixth "F." Additional risk factors include rapid weight loss (which mobilizes fat stores and alters cholesterol secretion), certain medications (such as fibrates, ceftriaxone, and oral contraceptives), diabetes mellitus (which impairs gallbladder emptying and increases infection risk), and conditions like Crohn's disease or cirrhosis that disrupt normal bile acid recirculation.

Symptoms of Cholecystitis

The symptoms of acute cholecystitis can be sudden and severe:

• Severe, constant pain in the upper right or center of the abdomen, often lasting for hours. This biliary colic typically begins after consuming a heavy, fatty meal, which normally triggers gallbladder contraction.
• Pain that may radiate to the right shoulder or back due to shared nerve pathways (phrenic nerve irritation and dermatomal referral patterns).
• Tenderness over the abdomen when touched. A classic sign is a positive Murphy's sign, where a patient feels sharp pain and stops inhaling when a doctor presses on the gallbladder area. This physical exam finding has a high specificity for gallbladder inflammation.
• Nausea and vomiting, which occur due to visceral nerve stimulation and the body's response to acute intra-abdominal pathology.
• Low-grade fever, reflecting the localized inflammatory response. High fevers are less common initially but may suggest progression to gangrene or abscess formation.
• Bloating and intolerance for fatty or spicy foods, which persist as the gallbladder struggles to concentrate and release bile effectively.

Chronic cholecystitis presents differently, characterized by recurrent, milder episodes of biliary colic rather than sustained acute inflammation. Over years, repeated irritation leads to a thickened, fibrotic, and non-functional gallbladder. Elderly patients and those with diabetes may exhibit "silent" presentations, lacking classic pain or fever and instead showing generalized malaise, anorexia, or confusion, which complicates timely diagnosis.

---

What is Cholangitis (Bile Duct Infection)?

Cholangitis is the inflammation of the bile ducts, the network of tubes that carry bile from the liver and gallbladder to the small intestine. Unlike cholecystitis, which is primarily an inflammatory issue, cholangitis is an infection that occurs when the ducts become blocked.

The condition is medically classified under ascending cholangitis because gut bacteria typically travel backward (ascend) from the duodenum through the ampulla of Vater into the obstructed biliary tree. When flow is halted, intraductal pressure rises, compromising the tight junctions between biliary epithelial cells. This breakdown of the mucosal barrier allows bacteria to translocate directly into the hepatic venous system and systemic circulation, making cholangitis a rapidly progressive and potentially fatal condition if biliary decompression is delayed.

Causes of Cholangitis

Cholangitis occurs due to a combination of biliary obstruction and a subsequent bacterial infection. Bile is normally sterile, but when it becomes stagnant due to a blockage, it creates a breeding ground for bacteria. The most common cause is a gallstone that has moved out of the gallbladder and become lodged in the common bile duct (choledocholithiasis). This accounts for approximately 50% to 80% of all acute cholangitis cases.

The microbiology of cholangitis is predominantly enteric in origin. The most frequently isolated organisms include Escherichia coli, Klebsiella pneumoniae, and Enterococcus species. In patients with recurrent infections, biliary stents, or prior hepatobiliary surgeries, anaerobic bacteria like Bacteroides and Clostridium species may also be involved, necessitating broader-spectrum antibiotic coverage.

Other causes of blockage include:

• Benign or malignant tumors (particularly pancreatic head adenocarcinoma, cholangiocarcinoma, or ampullary tumors).
• Strictures (narrowing) of the bile ducts, which can be primary (Primary Sclerosing Cholangitis) or secondary to prior surgery, trauma, or radiation therapy.
• Complications from procedures like an ERCP (Endoscopic Retrograde Cholangiopancreatography), where introduced contrast or instruments can transiently increase ductal pressure and introduce pathogens.
• Parasitic infections such as liver flukes (Clonorchis sinensis, Ascaris lumbricoides), which are more prevalent in endemic regions of Asia and South America.
• Immunocompromised states, including advanced HIV/AIDS, which can predispose patients to opportunistic biliary infections and sclerosing cholangitis-like syndromes.

Symptoms of Cholangitis

Cholangitis is a more systemic and often more severe illness. The classic presentation is known as Charcot's triad, which includes:

1. Fever with shaking chills (rigors) - Indicative of bacteremia and systemic inflammatory response syndrome (SIRS).
2. Jaundice (yellowing of the skin and whites of the eyes) - Caused by conjugated hyperbilirubinemia as bile backs up into the bloodstream.
3. Right upper quadrant (RUQ) abdominal pain - Resulting from acute distension and inflammation of the biliary tree.

In severe cases, the condition can progress to Reynolds' pentad, which adds two more critical signs, indicating sepsis and impending multi-organ dysfunction: 4. Hypotension (low blood pressure) - Driven by profound vasodilation, capillary leak, and distributive shock. 5. Altered mental status (confusion or lethargy) - Caused by cerebral hypoperfusion, hepatic encephalopathy in the setting of underlying liver disease, or severe systemic toxicity.

The presence of jaundice is a key differentiating factor, signaling a blockage that is affecting the entire biliary system and causing bilirubin to back up into the bloodstream. Patients with cholangitis may also exhibit dark urine (bilirubinuria), pale/clay-colored stools (absence of stercobilin), and generalized pruritus (itching) due to bile salt deposition in the skin. It is important to note that not all patients present with the full triad; studies show only 20-50% of patients exhibit all three classic signs initially. Elderly patients, in particular, may present solely with hypotension, tachycardia, or altered mental status without significant pain or fever, masking the true severity until rapid deterioration occurs.

*Video: Dirty Medicine provides a detailed explanation of the differences between various gallbladder and bile duct conditions.*

---

How Doctors Differentiate and Diagnose the Conditions

A precise diagnosis is critical because the treatment strategies are very different. Doctors use a combination of physical exams, lab tests, and imaging to distinguish between cholangitis and cholecystitis. Clinical guidelines, particularly the Tokyo Guidelines (TG18), are frequently utilized worldwide to standardize the diagnosis, grade severity, and determine the appropriate management pathway for both conditions.

Physical Examination and Lab Tests

• Physical Exam: A positive Murphy's sign strongly suggests cholecystitis. In cholangitis, a patient may appear more acutely ill (septic), with high fever, jaundice, and possible confusion. Palpation may reveal hepatomegaly (enlarged liver) due to biliary congestion, and in advanced cases, abdominal guarding or rebound tenderness if peritonitis develops from microperforations or severe inflammation.
• Blood Tests: Both conditions may show an elevated white blood cell count (leukocytosis), indicating inflammation or infection. However, lab tests for cholangitis will also show significantly elevated levels of bilirubin (causing jaundice) and liver enzymes like alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT), which points to a blockage in the bile ducts (a cholestatic pattern). Transaminases (AST/ALT) may be mildly elevated but typically do not reach the extreme levels seen in acute viral hepatitis. In cholangitis, blood cultures are essential; approximately 30-60% of patients will yield positive results, guiding targeted antibiotic therapy. Procalcitonin and C-reactive protein (CRP) levels are often measured to assess sepsis severity and track response to antimicrobial treatment. Conversely, in isolated cholecystitis, liver function tests are frequently normal or only mildly deranged, and amylase/lipase are checked to rule out concurrent gallstone pancreatitis.

Imaging Studies

• Ultrasound: This is usually the first imaging test performed. For cholecystitis, it can show gallstones, thickening of the gallbladder wall (>4mm), pericholecystic fluid, and a distended gallbladder (hydrops). The sonographic Murphy's sign increases diagnostic accuracy. For cholangitis, it may reveal a dilated (widened) common bile duct (>8mm, or >10mm in post-cholecystectomy patients). A recent case study published in the International Journal of Emergency Medicine highlighted how Point of Care Ultrasound (POCUS) can rapidly identify severe forms like emphysematous cholecystitis by detecting gas in the gallbladder (a "champagne sign").
• HIDA Scan (Cholescintigraphy): When ultrasound results are equivocal, particularly in suspected acalculous cholecystitis, a HIDA scan is highly sensitive. A radioactive tracer is injected intravenously; if the tracer fails to visualize the gallbladder within 60-90 minutes despite entering the small intestine, cystic duct obstruction is confirmed.
• CT Scan: Provides a more detailed view of the abdomen to confirm the diagnosis and rule out complications like abscesses or perforation. Contrast-enhanced CT can show gallbladder wall edema, pericholecystic fat stranding, and biliary dilation. It is also superior for evaluating surrounding organs to rule out pancreatic cancer or other malignancies causing extrinsic ductal compression.
• MRCP (Magnetic Resonance Cholangiopancreatography): A non-invasive MRI scan that provides highly detailed, three-dimensional images of the intrahepatic and extrahepatic bile ducts, gallbladder, and pancreatic duct without radiation. It is the gold standard non-invasive imaging modality for visualizing choledocholithiasis, strictures, and anatomical variants.
• ERCP (Endoscopic Retrograde Cholangiopancreatography): An invasive procedure that combines endoscopy and X-rays. While it can be used for diagnosis, it is primarily a therapeutic tool used to treat cholangitis by removing the blockage. ERCP allows direct visualization, sphincterotomy, stone extraction with balloons or baskets, and stent placement. Due to its invasive nature and risk of complications (like post-ERCP pancreatitis), it is generally reserved for cases requiring immediate intervention or when MRCP confirms ductal pathology.

!Comparison of Cholecystitis and Cholangitis Image: An infographic comparing the key features of cholecystitis and cholangitis. Source: MedicinePods

Differential diagnosis is a crucial part of the clinical workup. Physicians must carefully rule out conditions that mimic biliary pathology, such as peptic ulcer disease, acute gastroenteritis, right lower lobe pneumonia, myocardial ischemia, Fitz-Hugh-Curtis syndrome (perihepatitis secondary to pelvic inflammatory disease), acute hepatitis, pancreatitis, and renal colic from right-sided nephrolithiasis. Careful correlation of symptom onset, laboratory patterns, and imaging findings narrows the diagnostic field and prevents misdirected therapy.

---

Comparative Treatment, Severity, and Outcomes

The urgency and approach to treatment highlight the fundamental difference in severity between the two conditions. Management is guided by disease severity grading, hemodynamic stability, and patient comorbidities, with multidisciplinary teams (gastroenterology, general surgery, interventional radiology, and critical care) frequently involved in complex cases.

Treating Cholecystitis

The definitive treatment for cholecystitis is cholecystectomy, the surgical removal of the gallbladder. This is often done laparoscopically and scheduled promptly after diagnosis, ideally within 72 hours of symptom onset. Early laparoscopic cholecystectomy has been shown to reduce hospital stays, lower complication rates, and decrease the likelihood of recurrent biliary events compared to delayed interval surgery. The procedure involves four small abdominal incisions, insertion of a camera (laparoscope), and careful dissection of the cystic artery and cystic duct before removing the organ through the umbilical port. Conversion to an open laparotomy is necessary in approximately 2-5% of cases due to severe inflammation, dense adhesions from prior abdominal surgeries, or anatomical uncertainties.

For critically ill patients who cannot tolerate surgery due to severe cardiopulmonary compromise or advanced age, percutaneous cholecystostomy tube placement serves as a vital bridging intervention. Guided by ultrasound or CT, interventional radiologists insert a drainage catheter directly into the gallbladder to decompress the infected organ. This minimally invasive approach stabilizes the patient, allowing the inflammation to subside before elective cholecystectomy is considered weeks or months later.

While waiting for surgery, patients receive supportive care, including:

• Intravenous (IV) fluids to correct dehydration from vomiting and decreased oral intake, while simultaneously maintaining adequate intravascular volume.
• Pain medication, typically non-steroidal anti-inflammatory drugs (NSAIDs) like ketorolac, which have dual benefits for pain relief and reduction of gallbladder inflammation, supplemented by opioids if pain is severe.
• Antibiotics to prevent or treat secondary infection, commonly targeting gram-negative rods and anaerobes with regimens such as ceftriaxone plus metronidazole or piperacillin-tazobactam, adjusted based on local resistance patterns and allergy profiles.

Treating Cholangitis

Cholangitis is a medical emergency that requires immediate intervention. Delay in biliary decompression is directly correlated with increased mortality. Treatment focuses on three main goals, aligned with the Surviving Sepsis Campaign and Tokyo Guidelines recommendations:

1. Aggressive IV antibiotics to control the systemic infection. Empiric therapy is initiated immediately after blood cultures are drawn, utilizing broad-spectrum agents that penetrate the biliary tract effectively (e.g., third-generation cephalosporins combined with metronidazole, carbapenems, or fluoroquinolones). Therapy is later narrowed based on culture sensitivities, typically continuing for 7 to 14 days depending on clinical response and source control.
2. Supportive care with IV fluids, electrolyte replacement, and vasopressor medications to support blood pressure if the patient is in septic shock. Close monitoring in an intensive care unit is often required for patients presenting with Reynolds' pentad or organ dysfunction.
3. Urgent biliary drainage to relieve the obstruction. Timing of intervention is severity-dependent: patients with severe (Grade III) cholangitis require drainage within 24 hours, while mild (Grade I) cases may allow for a 24-48 hour window following initial antibiotic therapy. This is most commonly done via ERCP, where a specialist can perform a sphincterotomy, remove the stone or sludge with specialized baskets or balloons, and place a plastic or fully covered self-expanding metal stent to ensure continuous drainage. If ERCP fails or is anatomically impossible, percutaneous transhepatic cholangiography (PTC) with external drainage or surgical common bile duct exploration serves as alternative life-saving measures.

Once the acute infection is controlled and biliary flow is restored, the underlying cause (like gallstones) is addressed, which may involve a cholecystectomy at a later date to prevent recurrent episodes. In cases of malignant obstruction causing cholangitis, definitive management involves multidisciplinary oncology planning, including stent exchanges, chemotherapy, radiation, or palliative care depending on disease stage and patient goals.

Patient Outcomes

With timely treatment, the prognosis for both conditions is generally good. However, cholangitis carries a higher mortality risk if not treated urgently, as it can rapidly progress to life-threatening sepsis, acute respiratory distress syndrome (ARDS), acute kidney injury, and multi-organ failure. Mortality rates for untreated severe cholangitis exceed 30%, though modern intensive care and timely endoscopic drainage have reduced this to approximately 5-10% in contemporary clinical practice. Complications of cholecystitis, such as gallbladder perforation, empyema, gangrene, or Mirizzi syndrome (where an impacted cystic duct stone compresses the common hepatic duct), are also serious but the immediate risk of systemic shock is lower. Long-term outcomes after cholecystectomy are excellent, with most patients returning to normal digestion without the need for enzyme replacement or dietary restrictions, though a minority may experience post-cholecystectomy syndrome characterized by persistent dyspepsia or bile acid diarrhea.

---

Prevention and Lifestyle Management

While not all biliary diseases can be prevented, adopting evidence-based lifestyle modifications significantly reduces the risk of developing gallstones, the primary precursor to both cholecystitis and cholangitis. Understanding modifiable risk factors empowers patients to take proactive steps in safeguarding their hepatobiliary health.

Dietary Modifications: A diet low in saturated fats, refined carbohydrates, and processed foods, while rich in fiber, lean proteins, and healthy fats, supports optimal bile composition. Soluble fiber (found in oats, legumes, and fruits) binds to bile acids in the intestine, promoting their excretion and forcing the liver to synthesize new bile acids from cholesterol, thereby lowering cholesterol saturation in bile. Conversely, rapid weight loss diets or fasting cause the liver to secrete additional cholesterol into bile while the gallbladder remains underutilized, dramatically increasing stone formation risk. Weight reduction should be gradual, aiming for no more than 1 to 2 pounds per week.

Hydration and Physical Activity: Maintaining adequate daily fluid intake prevents bile from becoming overly concentrated. Regular aerobic exercise improves gallbladder motility, enhances insulin sensitivity, and helps maintain a healthy body mass index, all of which are protective against biliary sludge and stone development.

Medical Monitoring and Medication Management: Patients with known asymptomatic gallstones, diabetes, or a history of biliary colic should maintain regular follow-ups with their primary care provider or gastroenterologist. Certain medications that affect cholesterol metabolism or gallbladder contractility (like oral contraceptives, hormone replacement therapy, fibrates, and somatostatin analogs) should be used judiciously and under medical supervision. In high-risk scenarios, such as during rapid weight loss following bariatric surgery, prophylactic ursodeoxycholic acid may be prescribed to dissolve nascent cholesterol crystals and prevent symptomatic gallstone formation.

Recognizing Red Flags: Education on warning signs is a critical component of prevention. Patients should seek prompt medical evaluation for persistent RUQ pain lasting longer than six hours, fever, dark urine, pale stools, or visible jaundice. Early intervention prevents simple biliary colic from progressing to full-blown cholecystitis or ascending cholangitis, reducing the need for emergency surgeries and intensive care admissions.

Frequently Asked Questions

What is the main difference between cholecystitis and cholangitis?

The primary difference lies in the anatomical location and underlying pathophysiology. Cholecystitis is the inflammation of the gallbladder itself, usually resulting from a stone obstructing the cystic duct. It is primarily a localized inflammatory process that can become secondarily infected. Cholangitis, however, is an infection of the bile ducts (the tubes that transport bile from the liver and gallbladder to the intestines) caused by obstruction of the common bile duct. This blockage leads to stagnant bile, bacterial overgrowth, and rapid translocation of pathogens into the bloodstream, making cholangitis inherently more systemic and acutely dangerous.

Can cholecystitis turn into cholangitis?

Yes, cholecystitis can progress to cholangitis under specific circumstances. If a gallstone migrates from the cystic duct into the common bile duct (a condition called choledocholithiasis) and creates an obstruction there, bile flow from the liver is impeded. This backup, combined with potential infection, can trigger ascending cholangitis. Additionally, severe, untreated cholecystitis can cause external inflammation that compresses the adjacent bile ducts, or a fistula may form between the gallbladder and biliary tree, introducing infected material into the ductal system. This progression is why early diagnosis and timely treatment of gallbladder disease are crucial to prevent life-threatening complications.

Is cholecystectomy always necessary after a first episode of cholecystitis?

In most cases, yes. While mild, uncomplicated cases of acute cholecystitis can initially be managed with antibiotics and supportive care, the recurrence rate for gallstone-related symptoms without surgery is exceptionally high. Studies indicate that up to 30% of patients managed conservatively will experience another biliary event within one year, and many will develop complications such as chronic cholecystitis, pancreatitis, or cholangitis. Therefore, surgical removal of the gallbladder is considered the gold standard definitive treatment. Exceptions are made for patients who are exceptionally poor surgical candidates due to severe cardiopulmonary disease, in whom long-term medical management or a percutaneous drainage tube may be the preferred alternative.

How long does it take to recover from ERCP for cholangitis?

Recovery time after an ERCP varies based on the complexity of the procedure and the patient's baseline health. Most patients require a 1- to 3-day hospital stay for IV antibiotics, hydration, and monitoring of vital signs and liver function tests. The immediate recovery involves watching for procedure-related complications, with post-ERCP pancreatitis being the most common concern (occurring in roughly 3-5% of cases). Once the patient tolerates oral intake, pain is controlled, and fever resolves, they are typically discharged with a course of oral antibiotics to complete at home. Full physiological recovery and normalization of liver enzymes usually occur within 2 to 4 weeks. Follow-up appointments are scheduled to ensure complete resolution and to plan for elective gallbladder removal if not already performed.

Can I eat normally after gallbladder surgery?

Most patients can resume a regular diet shortly after laparoscopic cholecystectomy, but gradual dietary adaptation is highly recommended during the initial recovery period. Immediately after surgery, patients should stick to clear liquids and bland, easily digestible foods, slowly advancing to a low-fat diet for the first few weeks. Because the gallbladder is no longer present to store and concentrate bile, the liver continuously drips bile directly into the small intestine. This can initially overwhelm the digestive system when faced with high-fat meals, potentially causing loose stools, bloating, or urgency (bile acid diarrhea). Over time, the bile ducts slightly dilate and adapt to partially take on the storage role, and most patients can eventually return to a completely normal diet, including fats, without long-term restrictions. If chronic diarrhea persists beyond a few months, bile acid sequestrants (like cholestyramine) can be prescribed effectively by a physician.

Final Thoughts

While both cholangitis and cholecystitis involve inflammation in the biliary system, they are not the same. Cholecystitis is inflammation of the gallbladder, while cholangitis is a dangerous infection of the bile ducts. Remembering the key differences—especially the presence of jaundice in cholangitis (Charcot's triad)—can help you understand the seriousness of the symptoms.

If you experience severe abdominal pain, fever, or jaundice, it is essential to seek immediate medical evaluation. A prompt and accurate diagnosis is the key to receiving the correct treatment and ensuring a good outcome.

---

References

• Cleveland Clinic. (2023). Cholangitis: Types, Symptoms, Treatment. Retrieved from https://my.clevelandclinic.org/health/diseases/cholangitis
• Medical News Today. (2025). Cholangitis vs. cholecystitis: Symptoms and treatment. Retrieved from https://www.medicalnewstoday.com/articles/cholangitis-vs-cholecystitis
• NCBI StatPearls. (2023). Cholangitis. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK558946/
• Mayo Clinic. (2024). Cholecystitis - Symptoms and causes. Retrieved from https://www.mayoclinic.org/diseases-conditions/cholecystitis/symptoms-causes/syc-20364867
• Johns Hopkins Medicine. Gallstones. Retrieved from https://www.hopkinsmedicine.org/health/conditions-and-diseases/gallstones
• Chae, M.S., & Kravchuk, O.A. (2025). Point of care ultrasound in rapid diagnosis of acute cholangitis and emphysematous cholecystitis: a case report. International Journal of Emergency Medicine. Retrieved from https://intjem.biomedcentral.com/articles/10.1186/s12245-025-00823-5
• Dirty Medicine. (2016). Cholecystitis vs. Cholelithiasis vs. Cholangitis vs. Choledocolithiasis. YouTube. Retrieved from https://www.youtube.com/watch?v=SEjtC2PUrTs